FID-022 / Fulgent Genetics - LARVOL DELTA

A First-in-Human Study of FID-022 in Solid Tumor Patients (clinicaltrials.gov) - P=N/A | N=120 | Recruiting | Sponsor: H. Lee Moffitt Cancer Center and Research Institute

First-in-human • New trial • Cachexia • Oncology • Pancreatic Cancer • Solid Tumor

Study of FID-022 in Participants With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=24 | Recruiting | Sponsor: Fulgent Pharma LLC. | Not yet recruiting ➔ Recruiting | Initiation date: Apr 2025 ➔ Jul 2025

Enrollment open • Monotherapy • Trial initiation date • Solid Tumor